MBRX News and Press, Moleculin Biotech Inc. From 09/23/22

Moleculin Biotech to Present at the Virtual Investor Innovations in Acute Myeloid Leukemia (AML) Spotlight Event PR Newswire – Live moderated video webcast with members of management to discuss its ongoing Phase 1/2 study of core technology in development, Annam...

Moleculin Selected to Present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care PR Newswire HOUSTON , Sept. 8, 2022 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinic...

Moleculin to Present at the H.C. Wainwright 24th Annual Global Investment Conference PR Newswire HOUSTON , Sept. 7, 2022 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical ...

Seres Therapeutics, Inc. ( NASDAQ: MBRX ), a biotech focused on microbiome therapeutics, added ~7% in the pre-market trading Wednesday after the company announced the completion of the rolling submission process seeking FDA approval for its lead asset SER-109. With the...

The U.S. Food and Drug Administration (FDA) granted orphan drug designation to Moleculin Biotech's ( NASDAQ: MBRX ) WP1122 to treat Glioblastoma Multiforme (GBM), a type of brain cancer. "Given the progress of our Phase 1 clinical trial in healthy volunteers, the stron...

Moleculin Receives FDA Orphan Drug Designation of WP1122 for the Treatment of Glioblastoma Multiforme PR Newswire - Glioblastoma is the most aggressive malignant primary brain tumor with serious unmet medical need HOUSTON , Sept. 6, 2022 /PRNewswi...

Moleculin Announces Completion of Third Single Ascending Dose (SAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK PR Newswire – Preliminary results of third cohort in the first-in-human Phase 1a allows Company to proceed to next single ascending dose (SA...

Moleculin Biotech press release ( NASDAQ: MBRX ): Q2 GAAP EPS of -$0.24. The Company ended the quarter with $58.0 million of cash. The Company believes that this cash is sufficient to meet its projected operating requirements, which include a forecasted increase ...

Moleculin Reports Second Quarter 2022 Financial Results and Provides Programs Update PR Newswire - Continued advancement across clinical and preclinical programs; on track with multiple milestones and key data readouts expected through the second half of 2022 -...

Moleculin Concludes Phase 1b and Opens Recruitment in Phase 2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases PR Newswire – Preliminary Phase 1b data demonstrated clinical activity, defined as stable disease or better ...